Chemical structure of molecule BMS-986242

oral IDO1 inhibitor

clinical candidate in Ph. I/II combo for cancer

reversed amide of linrodostat

ACS Med. Chem. Lett., Jan. 28, 2021

Bristol Myers Squibb, Lawrence Township, NJ

The BMS IDO1 inhibitor, BMS-986242, is a clinical candidate in a Ph. I/II study in combination with nivolumab for cancer. Like me, you probably had to look twice at…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.